On December 12th, a reception was held in the House of Industry in honor of Philipp von Lattorff, who had received the Great Golden Medal of Honor for services to the Republic of Austria on November 25th. Von Lattorff was General Director of the Boehringer Ingelheim Regional Center Vienna (RCV) from 2013 to 2023 and during this time, among other things, was President of Pharmig, Vice President of the Industrial Association and active in the Chemical Industry Association of the Chamber of Commerce. Philipp von Lattorff is currently a member of the FORWIT Council, which advises the federal government on research, science, innovation and technology development.
The guests included high-ranking representatives from politics, business and science, including Economics Minister Martin Kocher, Science Minister Martin Polaschek and Foreign Minister Alexander Schallenberg.
In his laudatory speech, Pavol Dobrocky, General Director of Boehringer Ingelheim RCV, highlighted his predecessor’s achievements: “The decoration recognizes his many years of commitment to Austria as a research and business location. Philipp von Lattorff not only worked for Boehringer Ingelheim, but also in many areas His goal was always to sustainably strengthen Austria’s innovative strength and increase the competitiveness of the location.”
Philipp von Lattorff thanked him for the trust he had placed in him and promised to continue to be fully committed to Austria’s major issues. “Austria must continue to be an internationally competitive location for research, development and innovation in the future.”
The award underlines the important role that Philipp von Lattorff played in strengthening Austria as a research and business location. “With his vision and tireless commitment, he contributed to making Austria more attractive as a business and research location and to developing Boehringer Ingelheim into a growth engine in Europe,” said Pavol Dobrocky.
About Boehringer Ingelheim RCV
The Boehringer Ingelheim Regional Center Vienna (RCV) manages the business with human and animal health products. In addition to Austria, the region includes over 30 countries, primarily in Central and Eastern Europe and Central Asia.
In addition, clinical research throughout the region is coordinated from Vienna. Vienna is a central location for cancer research as well as for biopharmaceutical research and production.
In 2023, Boehringer Ingelheim RCV achieved total revenues of 1,383.4 million euros. 4,686 people were employed in the region, including 3,247 in Austria.
OTS ORIGINAL TEXT PRESS RELEASE UNDER THE EXCLUSIVE RESPONSIBILITY OF THE SENDER FOR CONTENT – WWW.OTS.AT | BOE